Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
Patents for C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
11/2005
11/01/2005US6960607 Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
11/01/2005US6960605 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
11/01/2005CA2130166C Surface coatings and a process for their production
10/2005
10/27/2005WO2005100334A1 Dipeptidyl peptidase-iv inhibitors
10/27/2005WO2005100329A1 Novel protecting reagents, protecting groups and methods of forming and using the same
10/27/2005WO2005100318A1 Alkanoic acids and their esters as antidiabetic agents
10/27/2005WO2005099687A2 Analogs of salinosporamide a
10/27/2005WO2004089366A8 Bicyclic compounds as nr2b receptor antagonists
10/27/2005US20050240023 Cathepsin cysteine protease inhibitors
10/27/2005US20050239860 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
10/27/2005US20050239854 Body weight gain inhibitors
10/27/2005US20050239851 Substituted benzoxazoles as estrogenic agents
10/27/2005US20050239790 Substituted hydroxyethylamine aspartyl protease inhibitors
10/27/2005DE102004016845A1 Phenylthioessigsäure-Derivate und ihre Verwendung Phenylthioacetic acid derivatives and their use
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1589006A1 Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents
10/26/2005EP1589000A2 (R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
10/26/2005EP1587821A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
10/26/2005EP1587799A1 Benzoxazole derivatives and their use as adenosine receptor ligands
10/26/2005EP1587798A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
10/25/2005US6958219 adding a labeled antibody, which binds to the autoinducer having a homoserine lactone ring with an N-acyl side chain, to a lysine-containing protein, and detection of immunospecific binding; N-(3-oxododecanoyl)-L-homoserine lactone
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/20/2005WO2005097784A1 Phenylthioacetic acid derivatives and use thereof
10/20/2005WO2005097765A1 Anaplastic lymphoma kinase modulators and methods of use
10/20/2005WO2005097114A2 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
10/20/2005WO2005096734A2 Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
10/20/2005WO2005055715A3 Insecticidal n-(heteroarylalkyl) alkanediamine derivatives
10/20/2005WO2003106413A3 Process for the preparation of oxazolidinones and method of use thereof
10/20/2005US20050234239 Method of forming a carbon-carbon or carbon-heteroatom linkage
10/20/2005US20050234126 Amide derivatives as inhibitors of the enzymatic activity of renin
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234109 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine
10/20/2005US20050234065 Dipeptidyl peptidase-IV inhibitors
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234052 Treatment for ocular infections
10/20/2005US20050234046 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
10/20/2005US20050233909 such as 6-(5-chlorobenzoxazol-2-yl)-2-(3-trifluoromethylphenoxy)pyridine, used on monocotyledonus or dicotyledonus weeds
10/20/2005CA2562140A1 Phenylthioacetic acid derivatives and use thereof
10/20/2005CA2561945A1 Non-imidazole heterocyclic compounds as histamine h3 receptor modulators
10/20/2005CA2561928A1 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
10/20/2005CA2559866A1 Anaplastic lymphoma kinase modulators and methods of use
10/19/2005EP1586564A1 8-azaprostaglandin derivatives and medicinal uses thereof
10/19/2005EP1586558A2 Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
10/19/2005EP1585726A1 Fused heterocyclic derivatives as ppar modulators
10/19/2005EP1585725A2 Compounds which mimic the chemical and biological properties of discodermolide
10/19/2005EP1463714A4 Vanilloid receptor ligands and their use in treatments
10/19/2005CN1685008A Synergistic UV absorber combination
10/19/2005CN1684949A Valerolactone compounds and perfume composition
10/19/2005CN1683370A Hetaryl-substd. heterocycles
10/19/2005CN1223588C Process for preparing alcohol by heterocyclic carboxylic ester
10/18/2005US6955915 Solid phase synthesis; photolithography
10/18/2005CA2294171C N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
10/13/2005WO2005095365A1 Oxazole-amine compounds for the treatment of neurodegenerative disorders
10/13/2005WO2005095364A1 Phenoxyacetic acid derivative and medicine containing the same
10/13/2005WO2005095363A1 Bicyclic compound and medicine containing the same
10/13/2005WO2005095350A1 Pyrazole compounds and uses related thereto
10/13/2005WO2005095334A1 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/13/2005WO2005040139A3 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
10/13/2005WO2004071447A9 Substituted azole derivatives as therapeutic agents
10/13/2005US20050228186 Simple stereocontrolled synthesis of salinosporamide A
10/13/2005US20050228031 Tyrosine kinase inhibitors
10/13/2005US20050228015 Substituted heteroaryl- and phenylsulfamoyl compounds
10/13/2005US20050227994 Decomposition inhibitor for extracellular matrix of cartilage
10/13/2005US20050227986 Vanilloid receptor ligands and their use in treatments
10/13/2005CA2562114A1 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/13/2005CA2559945A1 Pyrazole compounds and uses related thereto
10/13/2005CA2557402A1 Pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
10/12/2005EP1583760A2 Substituted heterocyclic compounds
10/12/2005EP1583749A1 Oxazole derivatives as inhibitors of cyclooxygenase
10/12/2005EP1583529A2 Amino acid phenoxy ethers
10/12/2005EP1539319A4 Crystallization system utilizing atomization
10/12/2005EP1194421B1 Selective npy (y5) antagonists
10/12/2005EP0977563B1 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
10/12/2005CN1681771A 4-(3, 3-dihalo-allyloxy)phenoxy alkyl derivatives
10/12/2005CN1681557A Methods for treating carbonic anhydrase mediated disorders
10/12/2005CN1680308A New 3-aryl-2-hydroxypropionic acid derivative I
10/12/2005CN1222519C Reverse hydroxamate inhibitors of matrix metalloproteinases
10/12/2005CN1222374C Extrusion die
10/12/2005CN1222287C Pharmaceutical formulations contg. zolmitriptan
10/11/2005US6953859 Production process for 5-alkyl-oxazolidin-2,4-dione
10/11/2005US6953858 A phenylalkyl secondary- and tertiary-amides enzyme inhibitors as viricides, for treating AIDS
10/11/2005US6953812 Carboxy and amide containing compound suitable for treatment and/or prevention of diseases wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, diabetes, disorders of the lipid metabolism, such as dyslipidemia
10/11/2005US6953797 Nitric oxide synthase inhibitor; antiinflammatory agents
10/06/2005WO2005092899A1 Inhibitors of histone deacetylase
10/06/2005WO2005092845A1 Substituted heteroaryl- and phenylsulfamoyl compounds
10/06/2005WO2005061427A3 Method for the production of substituted 2-(phenoxymethyl)-benzoic acids
10/06/2005US20050222426 A compound selected from the group consisting of 1,2,3-benzotriazol-2-yl-L-alanine, 5-carboxy-1,2,3-benzotriazol-2-yl-L-alanine, and 5-carboxy-1,2,3-benzotriazol-1-yl-L-alanine.
10/06/2005US20050222423 Carboxylic acid derivative
10/06/2005US20050222254 Sulfonamide compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222227 Oxazole-amine compounds for the treatment of neurodegenerative disorders
10/06/2005US20050222223 And oxazole sulfonamides: 3-(2-{1-[(4-Chloro-benzenesulfonyl)-(2,5-difluoro-phenyl)-amino]-ethyl}-thiazol-5-yl)-propionic acid; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis
10/06/2005US20050222222 1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxo-ethylamino]-1-oxo-propyl]-4-[bis-(4-fluorophenyl)methyl]piperazine; inhibiting dipeptidyl peptidase IV or for treating Type II diabetes
10/06/2005US20050222215 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
10/06/2005US20050222129 Non-imidazole heterocyclic compounds
10/06/2005US20050222089 taxane is prepared by esterifying an appropriate baccatin carrying a C-13 hydroxyl functional group with an acid derivative and is obtained by controlled saponification
10/06/2005DE10361794B3 Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese Optically active heteroaromatic beta-hydroxy ester, and processes for their preparation and their use as intermediates in the total synthesis of epothilone-
10/06/2005CA2559733A1 Inhibitors of histone deacetylase
10/06/2005CA2559035A1 Substituted heteroaryl- and phenylsulfamoyl compounds
10/05/2005EP1581521A1 Fused heterocyclic derivatives as ppar modulators
10/05/2005EP1581516A2 3-heterocyclic benzylamide derivatives as potassium channel openers
1 ... 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 ... 210